Skip to main content

Table 1 Descriptive statistics of clinical measures

From: Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center

Variable

All men (n = 565)

Age (years)

65.0 (60.0—70.0)

PSA (ng/ml)

7.8 (4.9 – 9.1)

PSAD (ng/ml/cm3)

0.17 (0.09 – 0.19)

Prostate volume (cm3)

53.7 (36.0–70.0)

Abnormal DRE (%)

198 (35.0)

Abnormal US (%)

170 (30.1)

PI-RADS 1 (%)

74 (13.1)

PI-RADS 2 (%)

31 (5.5)

PI-RADS 3 (%)

103 (18.2)

PI-RADS 4 (%)

220 (38.9)

PI-RADS 5 (%)

137 (24.2)

ISUP 1 (%)

41 (7.3)

ISUP 2 (%)

148 (26.2)

ISUP 3 (%)

85 (15.0)

ISUP 4 (%)

41 (7.3)

ISUP 5 (%)

45 (8.0)

No tumor (%)

205 (36.3)

PCa (%)

360 (62.7)

csPCa (%)

318 (56.3)

nsPCa (%)

42 (7.4)

mpMRI in house (%)

419 (74.2)

mpMRI external (%)

146 (25.8)

  1. Table 1 shows the means and interquartile ranges or valid percentages of the collected patient data
  2. PSA prostate-specific antigen, PSAD prostate-specific antigen density, DRE digital rectal examination, US transrectal ultrasound, PI-RADS The Prostate Imaging—Reporting and Data System Version 2 (PI-RADS™ v2.1), ISUP International Society of Urological Pathology, CDR cancer detection rate, PCa, prostate cancer, csPCa clinically significant prostate cancer defined as Gleason ≥ 3 + 4, nsPCa non-clinically significant cancer defined as Gleason ≤ 6
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us